Kadence Bio
Clinical-stage biopharmaceutical company developing small-molecule therapeutics for sexual and mental health. The organization advances natural-product-inspired medicinal chemistry through preclinical pharmacology and translational studies and has progressed a lead orally administered, on‑demand candidate into Phase 1 clinical evaluation with regulatory approvals in the US and UK.
Industries
Nr. of Employees
small (1-50)
Products
Investigational oral on‑demand small‑molecule for premature ejaculation (lead asset)
A fast-acting, orally administered small-molecule candidate developed for on‑demand use to delay ejaculation; progressed into Phase 1 clinical safety and pharmacokinetic evaluation.
Investigational oral on‑demand small‑molecule for premature ejaculation (lead asset)
A fast-acting, orally administered small-molecule candidate developed for on‑demand use to delay ejaculation; progressed into Phase 1 clinical safety and pharmacokinetic evaluation.
Services
Collaborative preclinical and clinical development
Partnership-based advancement of small-molecule candidates from discovery through first-in-human studies, including CRO-managed clinical operations and regulatory submissions.
Collaborative preclinical and clinical development
Partnership-based advancement of small-molecule candidates from discovery through first-in-human studies, including CRO-managed clinical operations and regulatory submissions.
Expertise Areas
- Clinical trial management (first-in-human studies)
- Translational drug development
- Small-molecule medicinal chemistry
- Natural-product-inspired drug discovery
Key Technologies
- Small-molecule medicinal chemistry
- In vitro pharmacology assays (e.g., SERT, PDE4 testing)
- Preclinical in vivo models
- Oral formulation development for rapid onset